VYXEOS® (daunorubicin and cytarabine) is intensive chemotherapy for secondary acute myeloid leukemia (sAML), indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasiarelated changes (AML-MRC) in adults and pediatric patients 1 year and older.